Replimune Q3 net loss $39.7M; cash $616M; RP1 melanoma achieves 36% ORR in IGNYTE cohort

Replimune Group, Inc.

2023-Q3 EPS reported -$2.25

Net loss $39.7M for fiscal Q3 ended Dec 31, 2022 vs $29.7M YoY; R&D expenses rose to $30.3M.
Raised ~$259M gross in upsized public offering; secured $200M non-dilutive debt facility ($30M drawn); cash runway into H2 2025.
Topline data from CERPASS trial (RP1+cemiplimab in CSCC) delayed to Q3 2023 from prior H1 2023.
IGNYTE cohort of RP1+Opdivo in anti-PD1 failed melanoma: 36% ORR, 20% CR in first 75 patients; target enrollment of 125 reached.
Collaboration with Roche for RP2/3 in CRC and HCC; appointed Christopher Sarchi as CCO.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Replimune Group, Inc. reported financial results for the fiscal third quarter ended December 31, 2022.

Period: the fiscal third quarter ended December 31, 2022
Result: reported results

Exact text from the filing

On February 9, 2023, Replimune Group, Inc. issued a news release announcing its financial results for the third quarter ended December 31, 2022 and certain corporate updates.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Replimune Group, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-014934

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.